Two independent biopsy series from patients with melanoma who had been treated with Vemurafenib or Dabrafenib + Trametinib showed that, compared with baseline, the expression of melanoma antigens was increased as well the number of infiltrating CD8+ T-cells [78]. The gene discussed is CD8A; the disease is melanoma.